^
    Back
    Association details:
    Biomarker:ROS1 rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO 2022
    Title:

    977P - Phase II study of brigatinib in patients with tyrosine kinase inhibitor (TKI)-naïve ROS1-rearranged advanced non-small cell lung cancer (NSCLC): Barossa cohort 1

    Published date:
    09/05/2022
    Excerpt:
    Brigatinib demonstrated encouraging antitumor activity in patients with TKI-naïve ROS1-rearranged advanced NSCLC.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Transl Oncol
    Title:

    Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer

    Published date:
    05/27/2020
    Excerpt:
    Brigatinib demonstrated modest activity in crizotinib-resistant ROS1-rearranged NSCLC. Its intracranial and systemic activity should be assessed in correlation with the underlying molecular mechanism of crizotinib resistance.
    DOI:
    10.1007/s12094-020-02376-w